Iloprost Zentiva Pharma (Iloprost)

Iloprost mimics the natural prostacyclin (PGI2) by activating IP receptors on vascular smooth‑muscle cells, raising intracellular cAMP levels. This cascade causes vasodilation of pulmonary and systemic arteries and inhibits platelet aggregation, which together alleviate hypertension and support ulcer healing.

The prescribed dose of Iloprost Zentiva Pharma is individualized by the treating physician based on the patient’s clinical status, severity of disease, and response to therapy. Dosage adjustments are made according to established clinical guidelines and patient tolerance.

Safety data for iloprost in pregnancy and lactation are limited, and the product’s pregnancy category is not established. Healthcare providers should weigh potential benefits against possible risks and consider alternative therapies when treating pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Iloprost belongs to the prostacyclin analog class, offering inhaled delivery that provides targeted pulmonary vasodilation with fewer systemic effects compared with intravenous prostacyclins. Unlike oral endothelin‑receptor antagonists, iloprost can be titrated multiple times daily, allowing rapid adjustment of therapeutic response.

Store Iloprost Zentiva Pharma at room temperature, below 25 °C. Keep the vial in its original packaging, protect it from moisture and direct sunlight, and avoid freezing to maintain product stability.

Iloprost Zentiva Pharma is supplied as an inhalation solution. The patient uses a calibrated nebulizer device to inhale the medication, typically several times per day as directed by the prescriber. Proper inhalation technique and device cleaning are essential for optimal delivery.

Serious risks include significant hypotension, severe bronchospasm, and bleeding complications such as pulmonary hemorrhage. Patients should be monitored closely for sudden drops in blood pressure, respiratory distress, or signs of bleeding, and therapy should be discontinued if these events occur.

Iloprost is contraindicated in patients with known hypersensitivity to iloprost or any component of the formulation, those with active severe bleeding, recent hemoptysis, or uncontrolled hypotension. Caution is also advised for individuals with severe pulmonary infection or unstable cardiovascular conditions.